Seres therapeutics announces initiation of enrollment in ser-155 phase 1b study cohort 2 in individuals undergoing allogeneic hematopoietic stem cell transplantation

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced that enrollment in cohort 2 in its ser-155 phase 1b study is underway. ser-155, an investigational oral microbiome therapeutic, is designed to reduce the incidence of gastrointestinal (gi) infections, bloodstream infections, and graft versus host disease (gvhd) in individuals undergoing allogeneic hematopoietic stem cell transplantation (allo-hsct).
MCRB Ratings Summary
MCRB Quant Ranking